Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

Original publication

DOI

10.1038/nrrheum.2017.200

Type

Journal article

Journal

Nature reviews. Rheumatology

Publication Date

01/2018

Volume

14

Pages

53 - 60

Addresses

Centre for Inflammation Biology and Cancer Immunology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Great Maze Pond, London, SE1 1UL, UK.

Keywords

RA-MAP Consortium, Humans, Arthritis, Rheumatoid, Cooperative Behavior, Genomics, Phenotype, Research, Biomedical Research, Industry, History, 21st Century, Biomarkers, United Kingdom